All revved up and ready to roll, Roche is handed the keys to a multibillion-dollar hemophilia market
Roche has a green light to greatly expand its sales effort behind Hemlibra, the landmark hemophilia drug that is making marketing life miserable at Shire.
The FDA has rolled out an approval for the global heavyweight to start selling their drug — a breakthrough that has nevertheless stirred some uneasiness on the safety side — to patients who have yet to develop factor VIII inhibitors. That market is several times larger than the initial group Roche gained access to last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.